ROS1 positive

The more methods we have to find #lungcancer #biomarkers like ALK, @ros1cancer @RETpositive @EGFRResisters the better for us all. Love seeing more use of liquid biopsies too - faster diagnosis is key. #BiomarkersMatter (@Yvonne_Diaz_)

#ASCO23 | Hall D1 | Sund 4:42pm CT Intracranial and Systemic Efficacy of Repotrectinib in Advanced ROS1 Fusion-positive (ROS1+) Non-small Cell Lung Cancer (NSCLC) and Central Nervous System Metastases (CNS mets) in the Phase 1/2 TRIDENT-1 @JessicaJLinMD ➡️ https://t.co/I4j2RKV3WG (@MGHCancerCenter)

@JuliaRotow discussing the important therapeutics and research advances in ALK and ROS1 NSCLC at Miami Cancer Meeting. @ros1cancer @ALKPositiveinc @alk_fusion @IASLC @isliquidbiopsy TESTING TESTING TESTING! @LUNGevity @LuisERaez1 @edgardo_ny (@ChristianRolfo)

Case 2 also in @JCOPO_ASCO: Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive #PancreaticCancer https://t.co/jjGTpXZyvi (@Aiims1742)

Brigatinib in crizotinib-naive ROS1 fusion-positive NSCLC @JSMO_official by Dr. Toshiaki Takahashi. Brigatinib demonstrated ORR of 67.9% (90% CI, 50.6-82.1) and met the pre-planned threshold boundary. #JSMO2023 #LCSM (@HHorinouchi)

TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors | Future Oncology https://t.co/V1PxnXq8iR @MNagasaka @oncoOuLungCA @BenjaminBesseMD @MP_3855 @LuisERaez1 #lcsm (@n8pennell)

Glad to share our review of #MET alterations in #NSCLC published in @LungCaJournal. ➡️https://t.co/kXbz7gUHeP cMET is a recurrent player in NSCLC. Congrats to our fellow @MandySakamoto. #LCSM. @ALKLungCancer, @EGFRResisters, @ros1cancer, @RETpositive, @metcrusaders (@TejasPatilMD)

How do you address resistance to first-line ROS1 TKI therapy in ROS1 fusion-positive lung cancers? Tune in as @JessicaJLinMD from @MGHThoracicOnc discusses the framework for considering later-line strategies at #TTLC23 @IASLC #LCSM @ros1cancer @ros1dersuk @MGHCancerCenter (@IASLC)

@AACR Annual Meeting '23: Pt Advocacy Programs, opportunities + deadlines: 1/11: Scientist↔Survivor program application 1/12: Pt abstracts due More info: https://t.co/XbbwdHslEJ @ALKLungCancer @EGFRResisters @KRASKickers @RETpositive @ros1cancer @OncoAlert (@christine_lovly)

To the amazing community of #lungcancer advocates - please submit an abstract to showcase your work @AACR 2023 Meeting. @alk_fusion @ALK_Research @ALKLungCancer @EgfrUk @EGFRResisters @KRASKickers @metcrusaders @RETpositive @ros1cancer @LUNGevity @GO2forLungCancr @lcfamerica (@christine_lovly)

Hi Dr - Does this approach treat lung cancers as well(RoS 1 positive) ..came to know about the drug through KBC episode (@vinod_bhat)

The novel brain-penetrant ROS1-selective inhibitor NVL-520 elicited clinical activity and was well tolerated in heavily pretreated patients with ROS1 fusion–positive NSCLC. @alexdrilon @MSKCancerCenter #lcsm https://t.co/jr3KnWhChn (@OncLive)

Dr. @JessicaJLinMD will provide the latest updates in the management of #ROS1 #RET #NTRK and #NRG1 fusion-positive lung cancer at #DCLung22 on Saturday, October 29, 2022. Get all of the latest updates in one place! Full agenda, faculty and registration at: https://t.co/rZMLIyUBL3 (@StephenVLiu)

Dr. @JessicaJLinMD will provide the latest updates in the management of #ROS1 #RET #NTRK and #NRG1 fusion-positive lung cancer at #DCLung22 on Saturday, October 29, 2022. Get all of the latest updates in one place! Full agenda, faculty and registration at: https://t.co/rZMLIyUBL3 (@StephenVLiu)

Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with #entrectinib 🔗https://t.co/zFBoMBzXX7 ✏️ @alexdrilon @rdoebele @barlesi @genentech @FoundationATCG @MSKCancerCenter @CUAnschutz #NTRK #NSCLC #cfDNA (@MolOncology)

Study suggests entrectinib prolongs survival in ROS1 #TKI naïve patients with ROS1 fusion-positive #NSCLC, with modest activity in patients with #CNS-only progression post-crizotinib 💊🫁 See the study by @alexdrilon, Salvatore Siena & colleagues ➡️ https://t.co/xGgYHOQyaE (@LungSummit)

Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with #entrectinib 🔗https://t.co/zFBoMBzXX7 ✏️ @alexdrilon @rdoebele @barlesi @genentech @FoundationATCG @MSKCancerCenter @CUAnschutz #NTRK #NSCLC #ctDNA (@MolOncology)

What's new in ROS1 fusion-positive cancers? @alexdrilon summarizes the latest data on emerging targeted therapies and includes updates for repotrectinib, taletrectinib, NVL-520, and combination lorlatinib and SHP2, MEK, and MET inhibitor programs. #TTLC22 #LCSM @sloan_kettering (@IASLC)

Interesting discussion here at #gotoWLC regarding situations with multiple drivers. What do you do with a FISH positive ROS1 and EGFR L858R? What do you do with 2 pathogenic EGFR? The panel is leaning into @JoelNealMD for guidance. #LCSM (@KellyMercierPh1)

A nice example of the importance of repeat #biomarker testing in #EGFR #NSCLC (first MET amp as resistance, then NRAS amp). Also highlights need for combo TKI trials. This scenario is generalizable across oncogenes. @rdoebele @EGFRResisters @ALKLungCancer @RETpositive @ros1cancer (@TejasPatilMD)

a. reactive alveolar type II pneumocytes in NSCLC cases (positive) b. known ROS1 positive NSCLC tissue (positive) c. cell lines known to express ROS1-fusions d. known ROS1 negative NSCLC e. all of the above (@RocheDiaUSA)

https://t.co/Wc5BdJBqUI @LuisERaez1 @OLACANCER1 @ACPinternists @UMiamiHealth @BaptistHealthSF @kRasKickers @ros1cancer @EGFRResisters @NTRKers @RETpositive @ALKLungCancer (@edgardo_ny)

Our paper Patient-reported outcomes STARTRK-2: a global phase II basket study of entrectinib for ROS1 positive NSCLC & NTRK +tumors ⁦@ros1cancer⁩ ⁦@NTRKers⁩ ⁦@ntrkconnectinfo⁩ ⁦@DrSarcoma⁩ ⁦@LuisPaz_Ares⁩ ⁦@alexdrilon⁩ https://t.co/5KQwpaJSJB (@ChristianRolfo)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion–Positive Non–Small-Cell Lung Cancer https://t.co/LGH0mwxxZX Great publication and study led by my previous "fellow"! Great job, Rafal! (@fred_hirsch)

#WLC21 @BeccaHeistMD @MGHThoracicOnc discusses progress In treating patients with more rare mutations in #lungcancer -ROS1, NTRK, RET, MET Exon 14 Skip alterations. #lcsm @gotoPER @ros1cancer @METCrusaders @RETpositive @NTRKers #womeninthoraciconcology (@Latinamd)

What happened to "ROS1-positive NSCLC patients who have been previously treated with one prior platinum chemotherapy and one prior ROS1 TKI?" Did it fail or will it come later? @alexdrilon (@wi_qiong)

Repotrectinib gets Breakthrough Therapy Designation by the US FDA for TKI-naïve ROS1 fusion-positive lung cancers. Congratulations to the TRIDENT-1 investigators and patients. https://t.co/iNeyYviX4U (@alexdrilon)

#LCSM @EgfrUk @EGFRResisters @alk_fusion @ALKLungCancer @ros1cancer @kRasKickers @METCrusaders @RETpositive @NTRKers @Lung_Fund @LUNGevity @GO2Foundation @daunrespiro @ALCASEItalia @IASLC (@ChristianRolfo)

.@VamsiVelcheti, of @nyulangone, on the current and emerging treatment options for patients with ALK- and ROS1-positive non–small cell lung cancer #lcsm https://t.co/ubdCNJJazQ (@OncLiveSOSS)

#LCSM @myESMO @AACR @ASCO @EGFRResisters @EgfrUk @ALKLungCancer @alk_fusion @kRasKickers @RETpositive @ros1cancer @NTRKers @daunrespiro @ALCASEItalia @LUNGFORCE @LUNGevity @GO2Foundation @Lung_Fund (@ChristianRolfo)

Another #LiquidBiopsy approved by FDA! More opportunities for TESTING our patients. The dream: have a equal access worldwide to this technology for all the patients. @isliquidbiopsy @OncoAlert @lcsmchat @EGFRResisters @ros1cancer @RETpositive @kRasKickers @NTRKers @ALKLungCancer (@ChristianRolfo)

#lungcancer community - last day to register for #ILCSC20! Virtual and free. Connect with people around the world. Pls join us! 8/21-8/23 @LUNGevity @EGFRResisters @ALKLungCancer @alk_fusion @ros1cancer @METCrusaders @RETpositive @NTRKers @kRasKickers @IASLC (@christine_lovly)

.@VamsiVelcheti, of @nyugrossman, discusses the current and emerging treatment options for patients with ALK- and ROS1-positive NSCLC. #lcsm https://t.co/MbfWCUMKIE (@OncLive)

.@LeviAGarraway, discusses the @EU_Commission's approval of entrectinib for solid tumors that harbor an NTRK fusion, as well as for the treatment of ROS1-positive, advanced NSCLC. #lcsm https://t.co/Vj3r3vwrkA (@OncLive)

Drs. @Alexdrilon & Robert Mocharnuk assess recent data supporting the use of investigational therapies for the treatment of ROS1 rearrangement–positive #NSCLC. https://t.co/TNvJ3aEHTc (@ReachMD)